Article Text

Download PDFPDF
CASE REPORT
Neuromyelitis optica spectrum disorder presenting as rhomboencephalitis
  1. Maria Stavrou1,2,3,
  2. Lucy Francis2,4,
  3. Nomathamsanqa Tshuma5,
  4. Klaus Schmierer2,3
  1. 1Centre of Clinical Brain Sciences, University of Edinburgh, Edinburgh
  2. 2Clinical Board: Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, United Kingdom
  3. 3The Blizard Institute (Neuroscience), Barts and the London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom
  4. 4Critical Care, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom
  5. 5Haematology Department, University College London, United Kingdom, London
  1. Correspondence to Dr Maria Stavrou, m.stavrou{at}ucl.ac.uk

Summary

Rhomboencephalitis, at least in its acute phase, is often a severely disabling syndrome, and can be life threatening. A range of underlying conditions can lead to this clinical syndrome. Rapid diagnosis to initiate treatment early is key to a beneficial outcome. We report the case of a 22 year old Afro-Caribbean woman, who presented with a two -week history of walking difficulties, upper limb incoordination and slurred speech. Her brainstem function deteriorated at pace, and she developed hypersomnia. A broad diagnostic approach led to prophylactic treatment for the most common infectious causes. This did not improve her symptoms. Non-infectious inflammatory causes were therefore considered and plasma exchange treatment was initiated leading to marked improvement within days. Screening for autoimmune conditions confirmed aquaporin-4 positive neuromyelitis optica spectrum disorder (NMOSD) as the underlying cause. Immunotherapy with rituximab was started. So far, no relapse has been observed. While the definition of NMOSD continues to be refined, aquaporin-4 testing should be considered early in patients presenting with rhomboencephalitis who do not respond to antibiotic and antiviral treatment. Vigilance and early intervention are key to limit morbidity and mortality from NMOSD.

  • brain stem / cerebellum
  • neurology
  • multiple sclerosis
  • neuroimaging
  • neurological injury

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors Article written by MS with case presentation written by LF. Critical revision of article by KS.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors .

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.